{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:11:52Z","timestamp":1768313512199,"version":"3.49.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","award":["DE026379"],"award-info":[{"award-number":["DE026379"]}],"id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","award":["DE026450"],"award-info":[{"award-number":["DE026450"]}],"id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sj\u00f6gren\u2019s Syndrome (SjS) results in loss of salivary and lacrimal gland excretion due to an autoimmune attack on these secretory glands. Conventional SjS treatments address the symptoms, but not the cause of disease. Recognizing this deficit of treatments to reverse SjS disease, studies were pursued using the fimbriae from enterotoxigenic <jats:italic>E. coli<\/jats:italic>, colonization factor antigen I (CFA\/I), which has anti-inflammatory properties. To determine if CFA\/I fimbriae could attenuate SjS-like disease in C57BL\/6.NOD-<jats:italic>Aec1Aec2<\/jats:italic> (SjS) females, the <jats:italic>Lactococcus lactis<\/jats:italic> (LL) 301 strain was developed to chromosomally express the <jats:italic>cfaI<\/jats:italic> operon. Western blot analysis confirmed CFA\/I protein expression, and this was tested in SjS females at different stages of disease. Repeated dosing with LL 301 proved effective in mitigating salivary flow loss and in reducing anti-nuclear antibodies (ANA) and inflammation in the submandibular glands (SMGs) in SjS females and in restoring salivary flow in diseased mice. LL 301 treatment reduced proinflammatory cytokine production with concomitant increases in TGF-\u03b2<jats:sup>+<\/jats:sup> CD25<jats:sup>+<\/jats:sup> CD4<jats:sup>+<\/jats:sup> T cells. Moreover, LL 301 treatment reduced draining lymph and SMG follicular T helper (Tfh) cell levels and proinflammatory cytokines, IFN-\u03b3, IL-6, IL-17, and IL-21. Such evidence points to the therapeutic capacity of CFA\/I protein to suppress SjS disease and to have restorative properties in combating autoimmune disease.<\/jats:p>","DOI":"10.1038\/s41598-023-46557-3","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T14:02:14Z","timestamp":1699538534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment with a Lactococcus lactis that chromosomally express E. coli cfaI\u00a0mitigates salivary flow loss\u00a0in a Sj\u00f6gren\u2019s syndrome-like disease"],"prefix":"10.1038","volume":"13","author":[{"given":"Ali","family":"Akgul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian Furlan","family":"Freguia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Maddaloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandria","family":"Voigt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuong Q.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil A.","family":"Fanger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary R.","family":"Fanger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"46557_CR1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/BOR.0000000000000473","volume":"30","author":"E Pontarini","year":"2018","unstructured":"Pontarini, E., Lucchesi, D. & Bombardieri, M. Current views on the pathogenesis of Sj\u00f6gren\u2019s syndrome. Curr. Opin. Rheumatol. 30, 215\u2013221 (2018).","journal-title":"Curr. Opin. Rheumatol."},{"key":"46557_CR2","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.autrev.2018.05.005","volume":"17","author":"K Psianou","year":"2018","unstructured":"Psianou, K. et al. Clinical and immunological parameters of Sj\u00f6gren\u2019s syndrome. Autoimmun. Rev. 17, 1053\u20131064 (2018).","journal-title":"Autoimmun. Rev."},{"key":"46557_CR3","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nrrheum.2013.110","volume":"9","author":"G Nocturne","year":"2013","unstructured":"Nocturne, G. & Mariette, X. Advances in understanding the pathogenesis of primary Sj\u00f6gren\u2019s syndrome. Nat. Rev. Rheumatol. 9, 544\u2013556 (2013).","journal-title":"Nat. Rev. Rheumatol."},{"key":"46557_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40266-013-0050-7","volume":"30","author":"RV Moerman","year":"2013","unstructured":"Moerman, R. V., Bootsma, H., Kroese, F. G. & Vissink, A. Sj\u00f6gren\u2019s syndrome in older patients: A etiology, diagnosis and management. Drugs Aging 30, 137\u2013153 (2013).","journal-title":"Drugs Aging"},{"key":"46557_CR5","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1001\/archinte.164.12.1275","volume":"64","author":"SS Kassan","year":"2004","unstructured":"Kassan, S. S. & Moutsopoulos, H. M. Clinical manifestations and early diagnosis of Sj\u00f6gren\u2019s syndrome. Arch. Intern. Med. 64, 1275\u20131284 (2004).","journal-title":"Arch. Intern. Med."},{"key":"46557_CR6","doi-asserted-by":"crossref","unstructured":"Helmick, C.G., Felson, D.T., Lawrence, R.C., Gabriel, S., Hirsch, R., Kwoh, C.K., Liang, M.H., Kremers, H.M., Mayes, M.D., Merkel, PA., Pillemer, S.R., Reveille, J.D., Stone, J.H., & National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 58, 15\u201325 (2008).","DOI":"10.1002\/art.23177"},{"key":"46557_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S1542-0124(12)70289-6","volume":"7","author":"CQ Nguyen","year":"2009","unstructured":"Nguyen, C. Q. & Peck, A. B. Unraveling the pathophysiology of Sj\u00f6gren syndrome-associated dry eye disease. Ocul. Surf. 7, 11\u201327 (2009).","journal-title":"Ocul. Surf."},{"key":"46557_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/ar3313","volume":"13","author":"N Delaleu","year":"2011","unstructured":"Delaleu, N., Nguyen, C. Q., Peck, A. B. & Jonsson, R. Sj\u00f6gren\u2019s syndrome: Studying the disease in mice. Arthritis Res. Ther. 13, 217 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"46557_CR9","doi-asserted-by":"crossref","unstructured":"Ridgway, W. M. et al. Chapter 6 Gene\u2013gene interactions in the NOD mouse model of type 1 diabetes. Adv. Immunol. 100, 151\u201375 (2008).","DOI":"10.1016\/S0065-2776(08)00806-7"},{"key":"46557_CR10","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/art.10258","volume":"46","author":"S Cha","year":"2002","unstructured":"Cha, S., Nagashima, H., Brown, V. B., Peck, A. B. & Humphreys-Beher, M. G. Two NOD Idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sj\u00f6gren\u2019s syndrome) on a healthy murine background. Arthritis Rheum. 46, 1390\u20131398 (2002).","journal-title":"Arthritis Rheum."},{"key":"46557_CR11","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/art.23214","volume":"58","author":"CQ Nguyen","year":"2008","unstructured":"Nguyen, C. Q., Hu, M. H., Li, Y., Stewart, C. & Peck, A. B. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sj\u00f6gren\u2019s syndrome: Findings in humans and mice. Arthritis Rheum. 58, 734\u2013743 (2008).","journal-title":"Arthritis Rheum."},{"key":"46557_CR12","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/BOR.0b013e328363eaa5","volume":"25","author":"CP Mavragani","year":"2013","unstructured":"Mavragani, C. P., Nezos, A. & Moutsopoulos, H. M. New advances in the classification, pathogenesis and treatment of Sj\u00f6gren's syndrome. Curr. Opin. Rheumatol. 25, 623\u2013629 (2013).","journal-title":"Curr. Opin. Rheumatol."},{"key":"46557_CR13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrrheum.2012.53","volume":"8","author":"M Ramos-Casals","year":"2012","unstructured":"Ramos-Casals, M., Brito-Zer\u00f3n, P., Sis\u00f3-Almirall, A., Bosch, X. & Tzioufas, A. G. Topical and systemic medications for the treatment of primary Sj\u00f6gren\u2019s syndrome. Nat. Rev. Rheumatol. 8, 399\u2013411 (2012).","journal-title":"Nat. Rev. Rheumatol."},{"key":"46557_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jaut.2012.05.014","volume":"39","author":"D Cornec","year":"2012","unstructured":"Cornec, D. et al. B cells in Sj\u00f6gren\u2019s syndrome: From pathophysiology to diagnosis and treatment. J. Autoimmun. 39, 161\u2013167 (2012).","journal-title":"J. Autoimmun."},{"key":"46557_CR15","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1517\/14712598.2011.605352","volume":"11","author":"PM Meiners","year":"2011","unstructured":"Meiners, P. M., Vissink, A., Kallenberg, C. G., Kroese, F. G. & Bootsma, H. Treatment of primary Sj\u00f6gren\u2019s syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?. Expert Opin. Biol. Ther. 11, 1381\u20132139 (2011).","journal-title":"Expert Opin. Biol. Ther."},{"key":"46557_CR16","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1365-2796.2009.02207.x","volume":"267","author":"F Perosa","year":"2010","unstructured":"Perosa, F., Prete, M., Racanelli, V. & Dammacco, F. CD20-depleting therapy in autoimmune diseases: From basic research to the clinic. J. Intern. Med. 267, 260\u2013277 (2010).","journal-title":"J. Intern. Med."},{"key":"46557_CR17","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1093\/rheumatology\/kez142","volume":"60","author":"RI Fox","year":"2021","unstructured":"Fox, R. I., Fox, C. M., Gottenberg, J. E. & D\u00f6rner, T. Treatment of Sj\u00f6gren\u2019s syndrome: Current therapy and future directions. Rheumatology (Oxford) 60, 2066\u20132074 (2021).","journal-title":"Rheumatology (Oxford)"},{"key":"46557_CR18","first-page":"217","volume":"37","author":"S Grigoriadou","year":"2019","unstructured":"Grigoriadou, S. et al. B cell depletion with rituximab in the treatment of primary Sj\u00f6gren\u2019s syndrome: What have we learnt?. Clin. Exp. Rheumatol. 37, 217\u2013224 (2019).","journal-title":"Clin. Exp. Rheumatol."},{"key":"46557_CR19","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/art.40093","volume":"69","author":"SJ Bowman","year":"2017","unstructured":"Bowman, S. J. et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheumatol. 69, 1440\u20131450 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"46557_CR20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.7326\/M13-1085","volume":"160","author":"V Devauchelle-Pensec","year":"2014","unstructured":"Devauchelle-Pensec, V. et al. Treatment of primary Sj\u00f6gren syndrome with rituximab: A randomized trial. Ann. Intern. Med. 160, 233\u2013242 (2014).","journal-title":"Ann. Intern. Med."},{"key":"46557_CR21","doi-asserted-by":"crossref","unstructured":"Tsuboi, H., Matsumoto, I., Hagiwara, S., Hirota, T., Takahashi, H., Ebe, H., Yokosawa, M., Yagishita, M., Takahashi, H., Kurata, I., Ohyama, A., Honda, F., Asashima, H., Miki, H., Umeda, N., Kondo, Y., Hirata, S., Saito, K., Tanaka, Y., Horai, Y., Nakamura, H., Kawakami, A. & Sumida, T. Effectiveness of abatacept for patients with Sj\u00f6gren's syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sj\u00f6gren's syndrome Endocrinopathy) trial. Mod. Rheumatol. 26, 891\u2013899 (2016).","DOI":"10.3109\/14397595.2016.1158773"},{"key":"46557_CR22","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1002\/acr.22052","volume":"65","author":"S Adler","year":"2013","unstructured":"Adler, S. et al. Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sj\u00f6gren\u2019s syndrome: A pilot study. Arthritis Care Res. (Hoboken) 65, 1862\u20131868 (2013).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"46557_CR23","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/JLB.5MR1020-057RR","volume":"109","author":"W Chen","year":"2021","unstructured":"Chen, W., Yang, F., Xu, G., Ma, J. & Lin, J. Follicular helper T cells and follicular regulatory T cells in the immunopathology of primary Sj\u00f6gren\u2019s syndrome. J. Leukoc. Biol. 109, 437\u2013447 (2021).","journal-title":"J. Leukoc. Biol."},{"key":"46557_CR24","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1002\/art.40165","volume":"69","author":"GM Verstappen","year":"2017","unstructured":"Verstappen, G. M. et al. Attenuation of follicular helper T cell-dependent B cell hyperactivity by abatacept treatment in primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheumatol. 69, 1850\u20131861 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"46557_CR25","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/mr\/roac011","volume":"33","author":"H Tsuboi","year":"2022","unstructured":"Tsuboi, H. et al. Abatacept ameliorates both glandular and extraglandular involvements in patients with Sj\u00f6gren\u2019s syndrome associated with rheumatoid arthritis: Findings from an open-label, multicenter, 1-year, prospective study: The ROSE (Rheumatoid Arthritis with Orencia Trial Toward Sj\u00f6gren\u2019s Syndrome Endocrinopathy) and ROSE II trials. Mod. Rheumatol. 33, 160\u2013168 (2022).","journal-title":"Mod. Rheumatol."},{"key":"46557_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.151955","volume":"53","author":"L de Wolff","year":"2022","unstructured":"de Wolff, L. et al. Long-term abatacept treatment for 48 weeks in patients with primary Sj\u00f6gren\u2019s syndrome: The open-label extension phase of the ASAP-III trial. Semin. Arthritis Rheum. 53, 151955 (2022).","journal-title":"Semin. Arthritis Rheum."},{"key":"46557_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0264-410X(93)90012-M","volume":"11","author":"R Edelman","year":"1993","unstructured":"Edelman, R. et al. Immunization of rabbits with enterotoxigenic E. coli colonization factor antigen (CFA\/I) encapsulated in biodegradable microspheres of poly (lactide-co-glycolide). Vaccine 11, 155\u2013158 (1993).","journal-title":"Vaccine"},{"key":"46557_CR28","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/0016-5085(84)90091-X","volume":"87","author":"DG Evans","year":"1984","unstructured":"Evans, D. G., Graham, D. Y., Evans, D. J. Jr. & Opekun, A. Administration of purified colonization factor antigens (CFA\/I, CFA\/II) of enterotoxigenic Escherichia coli to volunteers. Gastroenterology 87, 934\u2013940 (1984).","journal-title":"Gastroenterology"},{"key":"46557_CR29","first-page":"1575","volume":"82","author":"M Schmidt","year":"1985","unstructured":"Schmidt, M., Kelly, E. P., Tseng, L. Y. & Boedeker, E. C. Towards an oral E. coli pilus vaccine for traveler\u2019s diarrhea: Susceptibility to proteolytic digestion. Gastroenterology 82, 1575 (1985).","journal-title":"Gastroenterology"},{"key":"46557_CR30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0264-410X(93)90013-N","volume":"11","author":"RH Reid","year":"1993","unstructured":"Reid, R. H. et al. Preclinical evaluation of microencapsulated CFA\/II oral vaccine against enterotoxigenic E. coli. Vaccine 11, 159\u2013167 (1993).","journal-title":"Vaccine"},{"key":"46557_CR31","doi-asserted-by":"publisher","first-page":"6733","DOI":"10.4049\/jimmunol.175.10.6733","volume":"175","author":"S Jun","year":"2005","unstructured":"Jun, S. et al. A live diarrheal vaccine imprints a Th2 cell bias and acts as an anti-inflammatory vaccine. J. Immunol. 175, 6733\u20136740 (2005).","journal-title":"J. Immunol."},{"key":"46557_CR32","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.4049\/jimmunol.178.3.1791","volume":"178","author":"J Ochoa-Rep\u00e1raz","year":"2007","unstructured":"Ochoa-Rep\u00e1raz, J. et al. Regulatory T cell vaccination without autoantigen protects against experimental autoimmune encephalomyelitis. J. Immunol. 178, 1791\u20131799 (2007).","journal-title":"J. Immunol."},{"key":"46557_CR33","doi-asserted-by":"publisher","first-page":"954","DOI":"10.4049\/jimmunol.181.2.954","volume":"181","author":"J Ochoa-Rep\u00e1raz","year":"2008","unstructured":"Ochoa-Rep\u00e1raz, J. et al. IL-13 production by regulatory T cells protects against experimental autoimmune encephalomyelitis independently of autoantigen. J. Immunol. 181, 954\u2013968 (2008).","journal-title":"J. Immunol."},{"key":"46557_CR34","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.4049\/jimmunol.181.4.2741","volume":"181","author":"I Kochetkova","year":"2008","unstructured":"Kochetkova, I., Trunkle, T., Callis, G. & Pascual, D. W. Vaccination without auto-antigen protects against collagen II-induced arthritis via immune deviation and regulatory T cells. J. Immunol. 181, 2741\u20132452 (2008).","journal-title":"J. Immunol."},{"key":"46557_CR35","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.4049\/jimmunol.1100530","volume":"187","author":"I Kochetkova","year":"2011","unstructured":"Kochetkova, I., Crist, K., Callis, G. & Pascual, D. W. Segregated regulatory CD39+ CD4+ T cell function: TGF-\u03b2-producing Foxp3- and IL-10-producing Foxp3+ cells are interdependent for protection against collagen-induced arthritis. J. Immunol. 187, 4654\u20134666 (2011).","journal-title":"J. Immunol."},{"key":"46557_CR36","doi-asserted-by":"publisher","first-page":"804","DOI":"10.4049\/jimmunol.1302018","volume":"192","author":"I Kochetkova","year":"2014","unstructured":"Kochetkova, I. et al. Oral Escherichia coli colonization factor antigen I (CFA\/I) fimbriae ameliorate arthritis via IL-35, not IL-27. J. Immunol. 192, 804\u2013816 (2014).","journal-title":"J. Immunol."},{"key":"46557_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117825","volume":"10","author":"M Maddaloni","year":"2015","unstructured":"Maddaloni, M. et al. Milk-based nutraceutical for treating autoimmune arthritis via the stimulation of IL-10- and TGF-\u00df-producing CD39+ regulatory T cells. PLoS One 10, e0117825 (2015).","journal-title":"PLoS One"},{"key":"46557_CR38","doi-asserted-by":"publisher","first-page":"6156","DOI":"10.1038\/s41598-020-62881-4","volume":"10","author":"AS Nelson","year":"2020","unstructured":"Nelson, A. S. et al. Oral therapy with colonization factor antigen I prevents development of type 1 diabetes in non-obese diabetic mice. Sci. Rep. 10, 6156 (2020).","journal-title":"Sci. Rep."},{"key":"46557_CR39","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.imlet.2021.07.009","volume":"239","author":"AS Nelson","year":"2021","unstructured":"Nelson, A. S. et al. Oral probiotic promotes indoleamine 2,3-dioxygenase- and TGF-\u03b2-producing plasmacytoid dendritic cells to initiate protection against type 1 diabetes. Immunol. Lett. 239, 12\u201319 (2021).","journal-title":"Immunol. Lett."},{"key":"46557_CR40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13075-021-02475-1","volume":"23","author":"A Akgul","year":"2021","unstructured":"Akgul, A. et al. Stimulation of regulatory T cells with Lactococcus lactis expressing enterotoxigenic E. coli colonization factor antigen 1 retains salivary flow in a genetic model of Sj\u00f6gren\u2019s syndrome. Arthritis Res. Ther. 23, 99 (2021).","journal-title":"Arthritis Res. Ther."},{"key":"46557_CR41","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1146\/annurev-food-022510-133640","volume":"2","author":"J Wells","year":"2011","unstructured":"Wells, J. Mucosal vaccination and therapy with genetically modified lactic acid bacteria. Annu. Rev. Food Sci. Technol. 2, 423\u2013445 (2011).","journal-title":"Annu. Rev. Food Sci. Technol."},{"key":"46557_CR42","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1128\/aem.61.7.2771-2774.1995","volume":"61","author":"N Klijn","year":"1995","unstructured":"Klijn, N., Weerkamp, A. H. & de Vos, W. M. Genetic marking of Lactococcus lactis shows its survival in the human gastrointestinal tract. Appl. Environ. Microbiol. 61, 2771\u20132774 (1995).","journal-title":"Appl. Environ. Microbiol."},{"key":"46557_CR43","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1128\/AEM.03221-12","volume":"79","author":"C Daniel","year":"2013","unstructured":"Daniel, C., Poiret, S., Dennin, V., Boutillier, D. & Pot, B. Bioluminescent Lactobacillus plantarum and Lactococcus lactis to study spatial and temporal persistence in living mice. Appl. Environ. Microbiol. 79, 1086\u20131094 (2013).","journal-title":"Appl. Environ. Microbiol."},{"key":"46557_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.639975","volume":"12","author":"K Szab\u00f3","year":"2021","unstructured":"Szab\u00f3, K. et al. The imbalance of circulating follicular T helper cell subsets in primary Sj\u00f6gren\u2019s syndrome associates with serological alterations and abnormal B-cell distribution. Front. Immunol. 12, 639975 (2021).","journal-title":"Front. Immunol."},{"key":"46557_CR45","first-page":"6697319","volume":"23","author":"TM Preisser","year":"2021","unstructured":"Preisser, T. M. et al. Recombinant Lactococcus lactis carrying IL-4 and IL-10 coding vectors protects against type 1 diabetes in NOD mice and attenuates insulitis in the STZ-induced model. J. Diabetes Res. 23, 6697319 (2021).","journal-title":"J. Diabetes Res."},{"key":"46557_CR46","doi-asserted-by":"publisher","first-page":"517166","DOI":"10.3389\/fbioe.2020.517166","volume":"8","author":"LM Tavares","year":"2020","unstructured":"Tavares, L. M. et al. Novel strategies for efficient production and delivery of live biotherapeutics and biotechnological uses of Lactococcus lactis: The lactic acid bacterium model. Front. Bioeng. Biotechnol. 8, 517166 (2020).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"46557_CR47","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.3389\/fimmu.2017.01961","volume":"8","author":"DP Cook","year":"2018","unstructured":"Cook, D. P., Gysemans, C. & Mathieu, C. Lactococcus lactis as a versatile vehicle for tolerogenic immunotherapy. Front. Immunol. 8, 1961 (2018).","journal-title":"Front. Immunol."},{"key":"46557_CR48","doi-asserted-by":"publisher","first-page":"5898","DOI":"10.3168\/jds.2014-7980","volume":"97","author":"H Kimoto-Nira","year":"2014","unstructured":"Kimoto-Nira, H. et al. Effects of ingesting milk fermented by Lactococcus lactis H61 on skin health in young women: A randomized double-blind study. J. Dairy Sci. 97, 5898\u20135903 (2014).","journal-title":"J. Dairy Sci."},{"key":"46557_CR49","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/1352458511398054","volume":"17","author":"JO Fleming","year":"2011","unstructured":"Fleming, J. O. et al. Probiotic helminth administration in relapsing-remitting multiple sclerosis: A phase 1 study. Mult. Scler. 17, 743\u2013754 (2011).","journal-title":"Mult. Scler."},{"key":"46557_CR50","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3109\/08830180903197498","volume":"28","author":"P Rottiers","year":"2009","unstructured":"Rottiers, P., De Smedt, T. & Steidler, L. Modulation of gut-associated lymphoid tissue functions with genetically modified Lactococcus lactis. Int. Rev. Immunol. 28, 465\u2013486 (2009).","journal-title":"Int. Rev. Immunol."},{"key":"46557_CR51","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/nbt840","volume":"21","author":"L Steidler","year":"2003","unstructured":"Steidler, L. et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat. Biotechnol. 21, 785\u2013789 (2003).","journal-title":"Nat. Biotechnol."},{"key":"46557_CR52","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/0030-4220(90)90238-N","volume":"69","author":"H Celenligil","year":"1990","unstructured":"Celenligil, H., Kansu, E., Ruacan, S., Eratalay, K. & Irkec, M. Characterization of peripheral blood and salivary gland lymphocytes in Sj\u00f6gren\u2019s syndrome. Oral Surg. Oral Med. Oral Pathol. 69, 572\u2013577 (1990).","journal-title":"Oral Surg. Oral Med. Oral Pathol."},{"key":"46557_CR53","first-page":"2438","volume":"34","author":"X Li","year":"2007","unstructured":"Li, X. et al. T regulatory cells are markedly diminished in diseased salivary glands of patients with primary Sj\u00f6gren\u2019s syndrome. J. Rheumatol. 34, 2438\u20132445 (2007).","journal-title":"J. Rheumatol."},{"key":"46557_CR54","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1177\/0961203307085248","volume":"17","author":"MF Liu","year":"2008","unstructured":"Liu, M. F., Lin, L. H., Weng, C. T. & Weng, M. Y. Decreased CD4+CD25+bright T cells in peripheral blood of patients with primary Sj\u00f6gren\u2019s syndrome. Lupus 17, 34\u201339 (2008).","journal-title":"Lupus"},{"key":"46557_CR55","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13075-022-02769-y","volume":"24","author":"M Keindl","year":"2022","unstructured":"Keindl, M. et al. Impaired activation of STAT5 upon IL-2 stimulation in Tregs and elevated sIL-2R in Sj\u00f6gren\u2019s syndrome. Arthritis Res. Ther. 24, 101 (2022).","journal-title":"Arthritis Res. Ther."},{"key":"46557_CR56","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.3389\/fimmu.2018.01755","volume":"9","author":"J Luo","year":"2018","unstructured":"Luo, J. et al. IL-2 inhibition of Th17 generation rather than induction of Treg cells is impaired in primary Sj\u00f6gren\u2019s syndrome patients. Front. Immunol. 9, 1755 (2018).","journal-title":"Front. Immunol."},{"key":"46557_CR57","doi-asserted-by":"publisher","first-page":"911151","DOI":"10.3389\/fimmu.2022.911151","volume":"13","author":"A Raugh","year":"2022","unstructured":"Raugh, A., Allard, D. & Bettini, M. Nature vs. nurture: FOXP3, genetics, and tissue environment shape Treg function. Front. Immunol. 13, 911151 (2022).","journal-title":"Front. Immunol."},{"key":"46557_CR58","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nri.2016.26","volume":"16","author":"MO Li","year":"2016","unstructured":"Li, M. O. & Rudensky, A. Y. T cell receptor signalling in the control of regulatory T cell differentiation and function. Nat. Rev. Immunol. 16, 220\u2013233 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"46557_CR59","doi-asserted-by":"publisher","first-page":"887354","DOI":"10.3389\/fmed.2022.887354","volume":"9","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Low dose interleukin-2 ameliorates Sj\u00f6gren\u2019s syndrome in a murine model. Front. Med. (Lausanne) 9, 887354 (2022).","journal-title":"Front. Med. (Lausanne)"},{"key":"46557_CR60","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12865-022-00524-1","volume":"23","author":"J Wen","year":"2022","unstructured":"Wen, J., Zhu, F., Yu, X., Xie, H. & Li, C. Low-dose interleukin-2 can improve salivary secretion but not lymphocyte infiltration of salivary glands in a murine model of Sj\u00f6gren\u2019s syndrome. BMC Immunol. 23, 49 (2022).","journal-title":"BMC Immunol."},{"key":"46557_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101547","volume":"58","author":"E Pontarini","year":"2021","unstructured":"Pontarini, E., Coleby, R. & Bombardieri, M. Cellular and molecular diversity in Sj\u00f6gren\u2019s syndrome salivary glands: Towards a better definition of disease subsets. Semin. Immunol. 58, 101547 (2021).","journal-title":"Semin. Immunol."},{"key":"46557_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102689","volume":"122","author":"HM Ren","year":"2021","unstructured":"Ren, H. M., Lukacher, A. E., Rahman, Z. S. M. & Olsen, N. J. New developments implicating IL-21 in autoimmune disease. J. Autoimmun. 122, 102689 (2021).","journal-title":"J. Autoimmun."},{"key":"46557_CR63","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41577-022-00693-5","volume":"22","author":"LSK Walker","year":"2022","unstructured":"Walker, L. S. K. The link between circulating follicular helper T cells and autoimmunity. Nat. Rev. Immunol. 22, 567\u2013575 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"46557_CR64","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.coi.2021.06.011","volume":"72","author":"SG Tangye","year":"2021","unstructured":"Tangye, S. G. & Ma, C. S. Molecular regulation and dysregulation of T follicular helper cells\u2014Learning from inborn errors of immunity. Curr. Opin. Immunol. 72, 249\u2013261 (2021).","journal-title":"Curr. Opin. Immunol."},{"key":"46557_CR65","doi-asserted-by":"crossref","unstructured":"Papillion, A. et al. Inhibition of IL-2 responsiveness by IL-6 is required for the generation of GC-TFH cells. Sci. Immunol. 4, eaaw7636 (2019).","DOI":"10.1126\/sciimmunol.aaw7636"},{"key":"46557_CR66","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1073\/pnas.75.3.1091","volume":"75","author":"J Parker","year":"1978","unstructured":"Parker, J., Pollard, J. W., Friesen, J. D. & Stanners, C. P. Stuttering: High-level mistranslation in animal and bacterial cells. Proc. Natl. Acad. Sci. U S A 75, 1091\u20131095 (1978).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"46557_CR67","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1128\/jb.173.15.4794-4798.1991","volume":"173","author":"KJ Leenhouts","year":"1991","unstructured":"Leenhouts, K. J., Kok, J. & Venema, G. Replacement recombination in Lactococcus lactis. J. Bacteriol. 173, 4794\u20134798 (1991).","journal-title":"J. Bacteriol."},{"key":"46557_CR68","first-page":"49","volume":"3","author":"L Steidler","year":"2003","unstructured":"Steidler, L. Gene exchange of thyA for interleukin-10 secures live GMO bacterial therapeutics. Discov. Med. 3, 49\u201351 (2003).","journal-title":"Discov. Med."},{"key":"46557_CR69","doi-asserted-by":"publisher","first-page":"R172","DOI":"10.1186\/ar3925","volume":"14","author":"BH Lee","year":"2012","unstructured":"Lee, B. H., Carcamo, W. C., Chiorini, J. A., Peck, A. B. & Nguyen, C. Q. Gene therapy using IL-27 ameliorates Sj\u00f6gren\u2019s syndrome-like autoimmune exocrinopathy. Arthritis Res. Ther. 14, R172 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"46557_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.995327","volume":"13","author":"ZI Goodwin","year":"2022","unstructured":"Goodwin, Z. I., Yang, X., Hoffman, C. & Pascual, D. W. Live mucosal vaccination stimulates potent protection via varied CD4+ and CD8+ T cell subsets against wild-type Brucella melitensis 16M challenge. Front. Immunol. 13, 995327 (2022).","journal-title":"Front. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46557-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46557-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46557-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T14:05:51Z","timestamp":1699538751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46557-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["46557"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-46557-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]},"assertion":[{"value":"14 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19489"}}